These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

555 related items for PubMed ID: 23833271

  • 1. Longitudinal amyloid imaging in mouse brain with 11C-PIB: comparison of APP23, Tg2576, and APPswe-PS1dE9 mouse models of Alzheimer disease.
    Snellman A, López-Picón FR, Rokka J, Salmona M, Forloni G, Scheinin M, Solin O, Rinne JO, Haaparanta-Solin M.
    J Nucl Med; 2013 Aug; 54(8):1434-41. PubMed ID: 23833271
    [Abstract] [Full Text] [Related]

  • 2. In vivo PET imaging of beta-amyloid deposition in mouse models of Alzheimer's disease with a high specific activity PET imaging agent [(18)F]flutemetamol.
    Snellman A, Rokka J, López-Picón FR, Eskola O, Salmona M, Forloni G, Scheinin M, Solin O, Rinne JO, Haaparanta-Solin M.
    EJNMMI Res; 2014 Aug; 4():37. PubMed ID: 25977876
    [Abstract] [Full Text] [Related]

  • 3. Astrocytosis precedes amyloid plaque deposition in Alzheimer APPswe transgenic mouse brain: a correlative positron emission tomography and in vitro imaging study.
    Rodriguez-Vieitez E, Ni R, Gulyás B, Tóth M, Häggkvist J, Halldin C, Voytenko L, Marutle A, Nordberg A.
    Eur J Nucl Med Mol Imaging; 2015 Jun; 42(7):1119-32. PubMed ID: 25893384
    [Abstract] [Full Text] [Related]

  • 4. PET imaging of brain with the beta-amyloid probe, [11C]6-OH-BTA-1, in a transgenic mouse model of Alzheimer's disease.
    Toyama H, Ye D, Ichise M, Liow JS, Cai L, Jacobowitz D, Musachio JL, Hong J, Crescenzo M, Tipre D, Lu JQ, Zoghbi S, Vines DC, Seidel J, Katada K, Green MV, Pike VW, Cohen RM, Innis RB.
    Eur J Nucl Med Mol Imaging; 2005 May; 32(5):593-600. PubMed ID: 15791432
    [Abstract] [Full Text] [Related]

  • 5. In vivo SPECT imaging of amyloid-β deposition with radioiodinated imidazo[1,2-a]pyridine derivative DRM106 in a mouse model of Alzheimer's disease.
    Chen CJ, Bando K, Ashino H, Taguchi K, Shiraishi H, Shima K, Fujimoto O, Kitamura C, Matsushima S, Uchida K, Nakahara Y, Kasahara H, Minamizawa T, Jiang C, Zhang MR, Ono M, Tokunaga M, Suhara T, Higuchi M, Yamada K, Ji B.
    J Nucl Med; 2015 Jan; 56(1):120-6. PubMed ID: 25476539
    [Abstract] [Full Text] [Related]

  • 6. Binding of the positron emission tomography tracer Pittsburgh compound-B reflects the amount of amyloid-beta in Alzheimer's disease brain but not in transgenic mouse brain.
    Klunk WE, Lopresti BJ, Ikonomovic MD, Lefterov IM, Koldamova RP, Abrahamson EE, Debnath ML, Holt DP, Huang GF, Shao L, DeKosky ST, Price JC, Mathis CA.
    J Neurosci; 2005 Nov 16; 25(46):10598-606. PubMed ID: 16291932
    [Abstract] [Full Text] [Related]

  • 7. Pharmacokinetics of [¹⁸F]flutemetamol in wild-type rodents and its binding to beta amyloid deposits in a mouse model of Alzheimer's disease.
    Snellman A, Rokka J, Lopez-Picon FR, Eskola O, Wilson I, Farrar G, Scheinin M, Solin O, Rinne JO, Haaparanta-Solin M.
    Eur J Nucl Med Mol Imaging; 2012 Nov 16; 39(11):1784-95. PubMed ID: 22801729
    [Abstract] [Full Text] [Related]

  • 8. Quantification of β-Amyloidosis and rCBF with Dedicated PET, 7 T MR Imaging, and High-Resolution Microscopic MR Imaging at 16.4 T in APP23 Mice.
    Maier FC, Keller MD, Bukala D, Bender B, Mannheim JG, Brereton IM, Galloway GJ, Pichler BJ.
    J Nucl Med; 2015 Oct 16; 56(10):1593-9. PubMed ID: 26251417
    [Abstract] [Full Text] [Related]

  • 9. Preclinical and clinical study on [18F]DRKXH1: a novel β-amyloid PET tracer for Alzheimer's disease.
    Xu M, Guo J, Gu J, Zhang L, Liu Z, Ding L, Fu H, Ma Y, Liang S, Wang H.
    Eur J Nucl Med Mol Imaging; 2022 Jan 16; 49(2):652-663. PubMed ID: 34292345
    [Abstract] [Full Text] [Related]

  • 10. Applicability of [11C]PIB micro-PET imaging for in vivo follow-up of anti-amyloid treatment effects in APP23 mouse model.
    Snellman A, Rokka J, López-Picón FR, Helin S, Re F, Löyttyniemi E, Pihlaja R, Forloni G, Salmona M, Masserini M, Solin O, Rinne JO, Haaparanta-Solin M.
    Neurobiol Aging; 2017 Sep 16; 57():84-94. PubMed ID: 28605642
    [Abstract] [Full Text] [Related]

  • 11. Neuroinflammation Appears Early on PET Imaging and Then Plateaus in a Mouse Model of Alzheimer Disease.
    López-Picón FR, Snellman A, Eskola O, Helin S, Solin O, Haaparanta-Solin M, Rinne JO.
    J Nucl Med; 2018 Mar 16; 59(3):509-515. PubMed ID: 28986511
    [Abstract] [Full Text] [Related]

  • 12. Evidence for astrocytosis in prodromal Alzheimer disease provided by 11C-deuterium-L-deprenyl: a multitracer PET paradigm combining 11C-Pittsburgh compound B and 18F-FDG.
    Carter SF, Schöll M, Almkvist O, Wall A, Engler H, Långström B, Nordberg A.
    J Nucl Med; 2012 Jan 16; 53(1):37-46. PubMed ID: 22213821
    [Abstract] [Full Text] [Related]

  • 13. Longitudinal amyloid imaging using 11C-PiB: methodologic considerations.
    van Berckel BN, Ossenkoppele R, Tolboom N, Yaqub M, Foster-Dingley JC, Windhorst AD, Scheltens P, Lammertsma AA, Boellaard R.
    J Nucl Med; 2013 Sep 16; 54(9):1570-6. PubMed ID: 23940304
    [Abstract] [Full Text] [Related]

  • 14. 11C-PiB and 124I-Antibody PET Provide Differing Estimates of Brain Amyloid-β After Therapeutic Intervention.
    Meier SR, Sehlin D, Roshanbin S, Falk VL, Saito T, Saido TC, Neumann U, Rokka J, Eriksson J, Syvänen S.
    J Nucl Med; 2022 Feb 16; 63(2):302-309. PubMed ID: 34088777
    [Abstract] [Full Text] [Related]

  • 15. Antibody-Based In Vivo PET Imaging Detects Amyloid-β Reduction in Alzheimer Transgenic Mice After BACE-1 Inhibition.
    Meier SR, Syvänen S, Hultqvist G, Fang XT, Roshanbin S, Lannfelt L, Neumann U, Sehlin D.
    J Nucl Med; 2018 Dec 16; 59(12):1885-1891. PubMed ID: 29853653
    [Abstract] [Full Text] [Related]

  • 16. Small-animal PET imaging of amyloid-beta plaques with [11C]PiB and its multi-modal validation in an APP/PS1 mouse model of Alzheimer's disease.
    Manook A, Yousefi BH, Willuweit A, Platzer S, Reder S, Voss A, Huisman M, Settles M, Neff F, Velden J, Schoor M, von der Kammer H, Wester HJ, Schwaiger M, Henriksen G, Drzezga A.
    PLoS One; 2012 Dec 16; 7(3):e31310. PubMed ID: 22427802
    [Abstract] [Full Text] [Related]

  • 17. Longitudinal assessment of cerebral β-amyloid deposition in mice overexpressing Swedish mutant β-amyloid precursor protein using 18F-florbetaben PET.
    Rominger A, Brendel M, Burgold S, Keppler K, Baumann K, Xiong G, Mille E, Gildehaus FJ, Carlsen J, Schlichtiger J, Niedermoser S, Wängler B, Cumming P, Steiner H, Herms J, Haass C, Bartenstein P.
    J Nucl Med; 2013 Jul 16; 54(7):1127-34. PubMed ID: 23729696
    [Abstract] [Full Text] [Related]

  • 18. Post-mortem analyses of PiB and flutemetamol in diffuse and cored amyloid-β plaques in Alzheimer's disease.
    Ikonomovic MD, Buckley CJ, Abrahamson EE, Kofler JK, Mathis CA, Klunk WE, Farrar G.
    Acta Neuropathol; 2020 Oct 16; 140(4):463-476. PubMed ID: 32772265
    [Abstract] [Full Text] [Related]

  • 19. Impact of partial volume effect correction on cerebral β-amyloid imaging in APP-Swe mice using [(18)F]-florbetaben PET.
    Brendel M, Delker A, Rötzer C, Böning G, Carlsen J, Cyran C, Mille E, Gildehaus FJ, Cumming P, Baumann K, Steiner H, Haass C, Herms J, Bartenstein P, Rominger A.
    Neuroimage; 2014 Jan 01; 84():843-53. PubMed ID: 24055703
    [Abstract] [Full Text] [Related]

  • 20. Use of T1-weighted/T2-weighted magnetic resonance ratio to elucidate changes due to amyloid β accumulation in cognitively normal subjects.
    Yasuno F, Kazui H, Morita N, Kajimoto K, Ihara M, Taguchi A, Yamamoto A, Matsuoka K, Takahashi M, Nakagawara J, Iida H, Kishimoto T, Nagatsuka K.
    Neuroimage Clin; 2017 Jan 01; 13():209-214. PubMed ID: 28003959
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 28.